Dr. Norman Wong, a scientific chief officer from Resverlogix Corp. made a presentation at the ESC Congress 2015 on RVX-28 inhibitor, functioning on lowering the CVD risk, in which new data were presented to further enhance the mechanism of RVX-28 on the reduction of CVD risk in adverse cardiovascular events.
RVX-28, also named as apabetalone, a potent inhibitor of BET inhibitor bromodomains that can be active orally, showed by the latest studies. Patients with atherosclerotic disease were involved in the study, and they were given RVX-28 in the SUSTAIN and ASSURE trials. For better identification of the underlying mechanism of RVX-28, scientists made primary human hepatocytes exposed to RVX-28, and with the application of micro-array techniques, decreases of gene expression were detected then.
The gene expression decreases mainly covered various genes including innate immunity, fatty acid synthesis, and cholesterol synthesis, etc. 19 out of 26 genes that are complement pathway component encoded were detected and 20 in 33 were for coagulation cascade component encoded.
Data from an additional whole blood study were also presented in the presentation and it’s showed that RVX-28 decreased atherogenesis while increased anti-atherogenesis. A combination analysis of the data gained from the two studies suggested the mechanism of RVX-28 on reducing CVD risk lays in the increased anti-atherogenesis.
The trial of orally taken RVX-28 will continue with the third phase trial soon, according to the presenter Dr. Norman Wong from Resverlogix. With the success of the trial, BET inhibitor may be studied for more such benefits.
The scientific data showed the underlying function route of RVX-28, making the understanding of RVX-28 up to a higher level, at the same time providing a brand new insight into the mechanism of RVX-28, which may lay a foundation for a better application of the BET inhibitor in clinic treatment.
Source from Resverlogix Corp news and the whole presentation can be viewed at the official website of European Society of Cardiology.